Study Identifies ALKBH5-SLC38A3 Axis as Regulator of Cardiac Aging

Researchers demonstrated that ALKBH5-mediated m6A demethylation promotes cardiac aging by reducing SLC38A3 and altering glutamine metabolism, indicating that early preventive intervention is required to avoid age-associated remodeling.

A study published in Circulation reported that expression of the m6A demethylase ALKBH5 is elevated in aged mammalian hearts and senescent cardiomyocyte models, resulting in reduced global m6A levels.

Researchers used adeno-associated virus serotype 9 (AAV9) to deliver short hairpin RNA (shRNA) targeting ALKBH5 in mice, finding that knockdown initiated in young adulthood attenuated senescence phenotypes and age-associated cardiac remodeling.

The researchers noted that initiating ALKBH5 knockdown in already aged hearts did not reverse established cardiac aging phenotypes, establishing a temporal boundary for efficacy.

Mechanistically, the study showed that ALKBH5-dependent m6A demethylation reduces the expression of the solute carrier SLC38A3, which in turn leads to reduced glutamine accumulation, impaired mitochondrial homeostasis, and elevated oxidative stress.

In vivo overexpression of SLC38A3 or dietary glutamine supplementation was shown to attenuate senescence-associated and cardiac aging-related phenotypes.

This study offers concrete evidence linking epitranscriptomic RNA methylation dynamics directly to tissue-specific metabolic decline during aging.

The temporal constraint—where early knockdown prevented dysfunction but late knockdown failed to reverse it—indicates that certain age-related cardiac phenotypes may transition into irreversible states, limiting the utility of late-stage genetic interventions.

By identifying SLC38A3 and glutamine depletion as key mediators of mitochondrial impairment, the work highlights metabolic replenishment as a potential alternative or adjunct to genetic therapies.

These findings expand the preclinical targets for age-related cardiac therapeutics to include epitranscriptomic modifiers (m6A erasers like ALKBH5) and specific amino acid transporters (SLC38A3).

The use of AAV9 vectors for delivery reinforces the therapeutic relevance of targeted gene therapies for localized cardiac rejuvenation.

Because the intervention requires early-stage administration to be effective, future clinical development targeting this pathway may be forced to utilize complex, long-term preventive trial structures rather than standard acute cardiovascular endpoints.

Preclinical testing of small-molecule ALKBH5 inhibitors to determine if pharmacological modulation can replicate the preventive effects of shRNA knockdown.

Investigation into whether SLC38A3 upregulation or targeted glutamine supplementation can successfully mitigate cardiac decline in translationally relevant larger animal models.